Sensitivity analyses of the primary efficacy endpoint in a randomized-withdrawal phase 3 trial of tapentadol extended release (ER) in patients with painful diabetic peripheral neuropathy (DPN)
Etropolski, M., Steup, A., Shapiro, D.Y., Okamoto, A., Haeussler, J.Volume:
33
Year:
2009
Language:
english
Journal:
Canadian Journal of Diabetes
DOI:
10.1016/S1499-2671(09)33156-1
File:
PDF, 448 KB
english, 2009